Summary
GlobalData’s report, “Urinary Tract Infections – Pipeline Assessment and Market Forecasts to 2017”, is an essential source of information and analysis on the global urinary tract infections market. The report identifies key trends shaping and driving the global urinary tract infections market, and also provides insight into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insight into the pipeline products in the global urinary tract infections segment.
Urinary Tract Infections (UTI) – Pipeline Assessment and Market Forecasts to 2017
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts
GlobalData’s analysis suggests that the global Urinary Tract Infection (UTI) market was worth $1.14billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.7% for the next eight years to reach $1.3billion by 2017. The market is expected to be driven by the increase in usage of newly launched antibiotics for the treatment of complicated urinary tract infections and the increase in the prevalence and diagnosis of urinary tract infections. The patent expiry of one of the most efficacious drugs, Levaquin, in 2010 is expected to drive market revenues down. The FDA has recently approved Sandoz’s generic version of Levofloxacin in 2010. The impact of patent expiry is expected to be softened by the increase in revenue contribution of recently launched carbapenems for the treatment of complicated urinary tract infections.
Scope
The report identifies key trends shaping and driving the global urinary tract infections market. The scope of the report includes:
- Annualized global urinary tract infections market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of antibiotics in the pipeline includecell wall synthesis inhibitor, dihydrofolate reductase inhibitor, topoisomerase inhibitor, colonizes the vaginal mucosa and to secrete substances that inhibit the growth of microbial pathogens, restores the susceptibility of Gram-negative pathogens which are resistant to ceftazidime, bactericidal and anti-infectives.
- Analysis of the current and future competition in the global UTIs market. Key market players covered include , Osel Inc, Achaogen , Cubist Pharmaceuticals, Novexel Inc (AstraZeneca), MerLion Pharmaceuticals GmbH, Tedec-Meiji Farma, S.A. and NovaBay Pharmaceuticals, Inc
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future of the UTI market.
Reasons to buy
The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying companies with the most promising product candidates in the pipeline.
- Develop business strategies by understanding the trends shaping and driving the global UTI market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global UTI market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global UTI market landscape? – Identify, understand and capitalize.
